TWI327919B - Precursor of n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme - Google Patents

Precursor of n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme Download PDF

Info

Publication number
TWI327919B
TWI327919B TW092131341A TW92131341A TWI327919B TW I327919 B TWI327919 B TW I327919B TW 092131341 A TW092131341 A TW 092131341A TW 92131341 A TW92131341 A TW 92131341A TW I327919 B TWI327919 B TW I327919B
Authority
TW
Taiwan
Prior art keywords
precursor
sulfatase
enzyme
purity
acetylgalactosamine
Prior art date
Application number
TW092131341A
Other languages
English (en)
Chinese (zh)
Other versions
TW200427459A (en
Inventor
Qin Minmin
M Henstrand John
N Zecherle Gary
J Wendt Dan
Chan Wai-Pan
Chen Lin
A Fitzpatrick Paul
M Starr Christopher
Swiedler Stuart
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of TW200427459A publication Critical patent/TW200427459A/zh
Application granted granted Critical
Publication of TWI327919B publication Critical patent/TWI327919B/zh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06012—N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
TW092131341A 2002-11-07 2003-11-07 Precursor of n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme TWI327919B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/290,908 US6866844B2 (en) 2002-11-07 2002-11-07 Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

Publications (2)

Publication Number Publication Date
TW200427459A TW200427459A (en) 2004-12-16
TWI327919B true TWI327919B (en) 2010-08-01

Family

ID=32312121

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092131341A TWI327919B (en) 2002-11-07 2003-11-07 Precursor of n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

Country Status (17)

Country Link
US (1) US6866844B2 (enExample)
EP (2) EP2327414B1 (enExample)
JP (1) JP4459059B2 (enExample)
CN (1) CN100374157C (enExample)
AR (1) AR042019A1 (enExample)
AU (1) AU2003290642B2 (enExample)
BR (1) BRPI0316039B1 (enExample)
CA (1) CA2502928C (enExample)
CY (1) CY1116164T1 (enExample)
DK (1) DK2327414T3 (enExample)
ES (2) ES2533770T3 (enExample)
IL (1) IL168435A (enExample)
MX (1) MXPA05004880A (enExample)
PT (2) PT1565209E (enExample)
SI (1) SI2327414T1 (enExample)
TW (1) TWI327919B (enExample)
WO (1) WO2004043373A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972124B2 (en) * 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
ES2366059T3 (es) * 2006-03-17 2011-10-14 Biomarin Pharmaceutical Inc. Ensayos para la detección de anticuerpos anti-enzimas lisosómicas.
CN101539550B (zh) * 2009-04-28 2012-05-23 李绍平 用于多糖的定性与定量分析方法
MX382443B (es) 2010-06-25 2025-03-11 Shire Human Genetic Therapies Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld).
PE20130589A1 (es) * 2010-06-25 2013-05-19 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
CN103068999A (zh) * 2010-08-20 2013-04-24 贝林格尔.英格海姆国际有限公司 通过在获自细胞培养物的液体中改变ph灭活蛋白酶的方法
US9896715B2 (en) 2011-12-20 2018-02-20 Jcr Pharmaceuticals Co., Ltd. Method for analyzing formyl glycine residue
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN105848746B (zh) * 2013-09-05 2019-07-09 豪夫迈·罗氏有限公司 用于层析重复利用的方法
FR3011468B1 (fr) * 2013-10-04 2015-12-04 Inventiva Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
TWI870412B (zh) * 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281225A (enExample) 1961-07-20
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3891757A (en) 1971-11-11 1975-06-24 Alza Corp Anaesthetic topical and percutaneous administration with selected promoters
SE387536B (sv) 1973-03-13 1976-09-13 Astra Laekemedel Ab Forfarande for framstellning av en lokalanestetisk beredning
AU5577101A (en) 2000-05-01 2001-11-12 Biomarin Pharmaceuticals Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly

Also Published As

Publication number Publication date
EP2327414B1 (en) 2015-01-07
CY1116164T1 (el) 2017-02-08
BR0316039A (pt) 2005-09-13
ES2445028T3 (es) 2014-02-27
AR042019A1 (es) 2005-06-08
US20040101524A1 (en) 2004-05-27
ES2533770T3 (es) 2015-04-15
CN1726046A (zh) 2006-01-25
PT1565209E (pt) 2014-02-13
EP1565209A2 (en) 2005-08-24
PT2327414E (pt) 2015-04-13
CN100374157C (zh) 2008-03-12
HK1157215A1 (en) 2012-06-29
AU2003290642B2 (en) 2008-07-10
BRPI0316039B8 (enExample) 2021-05-25
CA2502928C (en) 2013-07-16
MXPA05004880A (es) 2005-07-22
BRPI0316039B1 (pt) 2017-08-29
CA2502928A1 (en) 2004-05-27
EP1565209A4 (en) 2008-01-02
DK2327414T3 (en) 2015-04-13
US6866844B2 (en) 2005-03-15
WO2004043373A2 (en) 2004-05-27
WO2004043373A3 (en) 2004-08-05
TW200427459A (en) 2004-12-16
SI2327414T1 (sl) 2015-05-29
IL168435A (en) 2014-07-31
EP1565209B1 (en) 2013-11-06
JP4459059B2 (ja) 2010-04-28
AU2003290642A1 (en) 2004-06-03
EP2327414A1 (en) 2011-06-01
JP2006510356A (ja) 2006-03-30

Similar Documents

Publication Publication Date Title
TWI870336B (zh) 重組人類酸性α-葡萄糖苷酶
DE69631544T2 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
TWI327919B (en) Precursor of n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
JP2006312648A (ja) 組換えα−Ｌ−イズロニダーゼ、その生成及び精製方法及びその欠失により引き起こされる疾病の処理方法
US20080260715A1 (en) Precursor N-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US20160303150A1 (en) Deuterated trehalose formulations and uses thereof
CA2443555C (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
AU2001255771A1 (en) Enzymes useful for treating and methods for treating MPS-VI and cell lines for producing such enzymes recombinantly
CN100457778C (zh) 睫状神经营养因子(cntf)突变体及其生产方法和其用途
HK1079713B (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
HK1079713A (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
CN101555284B (zh) 截短型人睫状神经营养因子活性片段及其融合蛋白
HK1157215B (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
JP7350019B2 (ja) 筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法
EP1716865A1 (en) Paraoxonase-containing pharmaceutical preparation
JP2025540135A (ja) 小児患者の乳児発症型ポンペ病の治療方法
HK40072878A (en) Method for capturing and purification of biologics
HK1087641A (en) Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent